Results 241 to 250 of about 21,836 (300)

Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways. [PDF]

open access: yesPharmaceuticals (Basel)
Hetta HF   +10 more
europepmc   +1 more source

New Perspectives on Antimicrobial Agents: Rezafungin. [PDF]

open access: yesAntimicrob Agents Chemother
Forrister NM, McCarty TP, Pappas PG.
europepmc   +1 more source

Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit. [PDF]

open access: yesAntibiotics (Basel)
Dermitzaki N   +5 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Echinocandins in Ocular Therapeutics.

Journal of Ocular Pharmacology and Therapeutics, 2017
Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
A. Patil, S. Majumdar
semanticscholar   +4 more sources

Echinocandins: The Expanding Antifungal Armamentarium

open access: yesClinical Infectious Diseases, 2015
The echinocandins are large lipopeptide molecules that, since their discovery approximately 41 years ago, have emerged as important additions to the expanding armamentarium against invasive fungal diseases. Echinocandins exert in vitro and in vivo fungicidal action against most Candida species and fungistatic action against Aspergillus species. However,
Daniel Aguilar-Zapata   +2 more
exaly   +5 more sources

Home - About - Disclaimer - Privacy